Answers are grounded in this paper and cite their sources.
Background: In osteoarthritis (OA), biochemical catabolic biomarkers receive increasing attention due to their superior sensitivity and objectivity.OA biochemical biomarkers have previously been studied in relation to structural changes.However, this study focused on early OA stages associated with knee pain.As a result of early diagnosis, patients with OA could be better managed, allowing for more personalized treatment options.Objective: In this multicenter Double Blind Randomized, placebo Controlled Cross-over Study we aimed to estimate the symptomatic efficacy and carry-over effects of AVOSOYA®300 one capsule/day on patients with early symptomatic knee OA "ESKOA".Patients and Methods: This study included 275 patients with early symptomatic knee osteoarthritis (ESKOA) according to Migliore, et al. [1] criteria.The patients were randomized to receive either ASU (n=140) or the same capsule placebo / day ( n=135) for the first 6 months.clinical assessment for pain by Visual Analogue Scale (100mm scale), Frequency of occurrence of pain/week and the necessity to use NSAID (and/or) analgesics/week was done.Laboratory urinary CTX-II (uCTX-II) and serum COMP (sCOMP) at the baseline, at six months and at 1year.Results: Our results showed that, the final included patients were 275 cases.Their ages ranged from 23 to 49 (41.17+5.73);They were 218 females and 57males.Among the ASU group, uCTXII, sCOMP, VAS score, pain frequency and NSDAIDs use /week were significantly improved after 12 months compared to that at baseline, 6 months and to that of placebo group.Conclusion: This RCT study showed that, in early symptomatic knee OA patients, AVOSOYA300mg/day supplement improve both subjective and objective parameters.Subjectively, it decreases the pain frequency and severity; Also minimize the NSAIDs/ pain killer needs.Objectively, this is confirmed through regression of catabolic cartilage biomarkers as uCTXII in the first 6 months of treatment and both uCTX-II and sCOMP afterwards.
No takes yet. Share an insight, caveat, or question.
Hesham Hamoud (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: